A Phase 2 interventional study of INBRX-109 and Placebo in Conventional Chondrosarcoma, sponsored by Inhibrx Biosciences, Inc. Active, not recruiting at 68 sites in 9 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by Inhibrx Biosciences, Inc · Phase 2, Interventional, and Treatment
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
This is a randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients. INBRX-109 is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
99 studies on the registry are indexed under Chondrosarcoma; 20 are open to participants now.
This study's enrollment of 206 is above the median of 52 across 72 interventional studies indexed under Chondrosarcoma.
Browse Chondrosarcoma studies →Inhibrx Biosciences, Inc is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IV every three weeks
Drug: INBRX-109
IV every three weeks
Drug: Placebo
Tetravalent DR5 Agonist Antibody
Placebo
Progression-free survival per RECISTv1.1 by real time IRR comparing INBRX-109 and placebo
Progression-free survival per RECISTv1.1 will be determined.
Time frame: 3 years
Overall survival of patients comparing INBRX-109 and placebo
Overall Survival in the ITT population
Time frame: 3 years
ORR per RECISTv1.1 by real-time IRR.
Tumor response will be determined by RECISTv1.1.
Time frame: 3 years
PFS per RECISTv1.1 by Investigator assessment
PFS per RECISTv1.1, by Investigator assessment, comparing INBRX-109 and placebo.
Time frame: 3 years
Quality of life assessed by EORTC questionnaire for cancer patients (QLQ-C30) comparing INBRX-109 and placebo
Quality of life will be determined.
Time frame: 3 years
DCR per RECISTv1.1 by real-time IRR
measured by DCR per RECISTv1.1, assessed by central real-time IRR, comparing INBRX-109 and placebo
Time frame: 3 years
DOR per RECISTv1.1 by real-time IRR
evaluate duration of response (DOR) per RECISTv1.1, assessed by central real-time IRR, comparing INBRX-109 and placebo
Time frame: 3 years
To evaluate the safety and tolerability of INBRX-109
Adverse events will be assessed and severity assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
Time frame: 3 years
Characterize the pharmacokinetics of INBRX-109.
AUC0-inf, AUC0-last, AUC0-21d, Cmax, Ctrough, Tmax will be estimated using a standard non-compartmental method as the data allow. Other PK parameters (λz, t½, Vd, CL, and accumulation ratios RCmax, RCtrough) will be calculated if data permit.
Time frame: 3 years
Immunogenicity of INBRX-109
Frequency of anti-drug antibodies against INBRX-109 will be determined.
Time frame: 3 years
Evaluate Quality of Life
QoL per EORTC QLQ-C30, EQ-5D-5L, PGI-C, PGI-S
Time frame: 3 years
Potential predictive response biomarkers
Evaluate the relationship between potential predictive response biomarkers and efficacy of INBRX-109
Time frame: 3 years
PFS per RECISTv1.1 by Investigator assessment
evaluate the anticancer efficacy of INBRX-109 as measured by PFS (by Investigator assessment) for crossover population after treatment with INBRX-109
Time frame: 3 years
ORR per RECISTv1.1 by Investigator assessment
evaluate the anticancer efficacy of INBRX-109 as measured by ORR (by Investigator assessment) for crossover population after treatment with INBRX-109
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2021 to primary completion in Sep 2025, 48 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Inhibrx Biosciences, Inc